ArticleCancers2021
The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma.
Mikhail S Chesnokov et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this papercites it
ArticleCancers2021
Mikhail S Chesnokov et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.